Novartis drug cuts cardiovascular risk in heart attack survivors
An experimental antibody being developed by Novartis has cut cardiovascular risk in patients who have survived a heart attack in a late-stage study. The Phase III CANTOS study met the primary endpoint showing that ACZ885 (canakinumab) reduced the risk of heart attack, stroke and cardiovascular death in people with a prior heart attack and inflammatory atherosclerosis.